|
Canada-0-HardwareRetail 公司名录
|
公司新闻:
- Venetoclax Is Effective in Small-Cell Lung Cancers with High . . . - PubMed
Purpose: Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually presenting as extensive disease, carrying a 3% 5-year survival Despite notable advances in SCLC genomics, new therapies remain elusive, largely due to a lack of druggable targets Experimental Design: We used a high-throughput drug screen to identify a venetoclax-sensitive SCLC subpopulation and validated
- Venetoclax is effective in small cell lung cancers with high BCL-2 . . .
Small cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually presenting as extensive disease, carrying a 3% five-year survival We used this platform to characterize the activity of venetoclax across cancer types and identify potential genomic predictors of response to this drug We found that a large subset of SCLC cell
- Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 . . .
Abstract Purpose: Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually presenting as extensive disease, carrying a 3% 5-year survival Despite notable advances in SCLC genomics, new therapies remain elusive, largely due to a lack of druggable targets Experimental Design: We used a high-throughput drug screen to identify a venetoclax-sensitive SCLC subpopulation and
- Predicting ROR1 BCL2 combination targeted therapy of small cell . . .
Small cell lung cancer (SCLC) has a 5-year survival rate of only 6 percent, with no approved targeted therapies, underscoring the need for novel therapeutics 1 While little progress was made over
- Venetoclax and Irinotecan for the Treatment of Relapsed or Refractory . . .
This phase I II trial investigates the best dose of venetoclax when given together with irinotecan and to see how well they work in treating patients with small cell lung cancer that has come back (relapsed) or does not respond to treatment (refractory) Chemotherapy drugs, such as venetoclax, work in different ways to stop the growth of tumor
- BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating . . .
Patients with small cell lung cancer (SCLC) generally have a poor prognosis, with an exceptionally high proliferative rate and a strong propensity for early metastasis, indicating the urgent need for novel therapies Lochmann TL, Floros KV, Naseri M, et al Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression Clin
- BCL- 2 mutant B7H6- CAR- T cells synergized with venetoclax for . . .
venetoclax could be a promising novel strategy against B7H6-expressing SCLCs and other solid tumors, providing the foundation for CAR-T cells and proapoptotic small molecules therapy in patients with SCLCs in a clinical trial BACKGROUND Small cell lung cancer (SCLC), accounting for approximately 15% of lung cancer cases,
- Johnson Johnson showcases latest advancements in cancer innovation . . .
Lung Cancer Patient-reported outcomes from the Phase 2 COCOON study – presented by Jill Feldman, Match-adjusted indirect comparison of IMBRUVICA® in combination with venetoclax versus acalabrutinib in combination with venetoclax in subjects with previously untreated CLL (Poster Abstract #PF587)
- Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks . . .
Background: No targeted drugs are currently available against small cell lung cancer (SCLC) BCL-2 family members are involved in apoptosis regulation and represent therapeutic targets in many malignancies Methods: Expression of BCL-2 family members in 27 SCLC cell lines representing all known four SCLC molecular subtypes was assessed by qPCR, Western blot and mass spectrometry-based proteomics
- Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 . . .
For example, Venetoclax is effective in small cell lung cancer with high bcl-2 expression (Lochmann et al , 2018) However, for the vast majority of tumor types and available therapeutic agents
|
|